Clinical Trials

Phase 1/2 Active not recruiting

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT01089101 2026-04-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

217 enrolled

Astrocytoma, Neurofibromatosis 1

NCT01364051 2026-04-13

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Phase 3 Active not recruiting

19 enrolled

Dermatologic

Melanoma

NCT04924608 2026-03-23

KOMET

145 enrolled 17 charts 3 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06188741 2026-03-12

NF114

Phase 2 Recruiting

200 enrolled

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06502171 2026-03-12

NF113

30 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

36 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT05101148 2026-02-23

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

24 enrolled

Phase 2 Not yet recruiting

Neurofibromatosis 1

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

41 enrolled

CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

32 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT02546661 2025-12-29

BISCAY

MyeloidOther hematologic neoplasm

117 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Phase 1 Recruiting

18 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT05309668 2025-12-18

SPRINKLE

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Phase 3 Active not recruiting

57 enrolled

Gastrointestinal

Gallbladder Neoplasms, Recurrence

NCT01933932 2025-11-19

SELECT-1

510 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00463814 2025-11-13

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

58 enrolled

Tumor-Agnostic

Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

BreastDermatologicGastrointestinalGenitourinaryThoracic

140 enrolled

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06735820 2025-07-03

MEKMDM2

45 enrolled

CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03095248 2025-04-22

SEL-TH-1601

Phase 2 Terminated

10 enrolled 9 charts